Nasdaq to delist BioXcel Therapeutics after Chapter 11 filing
Nasdaq notified BioXcel Therapeutics that its common stock will be delisted due to its Chapter 11 filing on Aug. 27, 2026. Trading will be suspended at the open on Sept. 8, 2026, with a Form 25-NSE to follow.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.